HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies

The intestinal immune compartment plays a central role in HIV pathogenesis, serving as an early site for viral replication and a significant reservoir for latent infection. Despite the success of antiretroviral therapy (ART) in suppressing plasma viremia, HIV persists indefinitely in latently infect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology Jg. 16; S. 1650852
Hauptverfasser: Lau, Jillian S. Y., Lewin, Sharon R., Telwatte, Sushama
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 2025
Schlagworte:
Animals
Anti-HIV Agents - therapeutic use
Gastrointestinal Microbiome - immunology
gene and cell therapies
gut-associated lymphoid tissue (GALT)
HIV Infections - drug therapy
HIV Infections - immunology
HIV Infections - virology
HIV persistence
HIV reservoir
HIV-1 - immunology
HIV-1 - physiology
Humans
Intestinal Mucosa - immunology
Intestinal Mucosa - virology
latency reversal
mucosal immunity
Virus Latency - drug effects
Virus Latency - immunology
antiretroviral penetration
gut-associated lymphoid tissue (GALT)
HIV cure strategies
latency reversal
HIV persistence
gene and cell therapies
HIV reservoir
mucosal immunity
ISSN:1664-3224, 1664-3224
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The intestinal immune compartment plays a central role in HIV pathogenesis, serving as an early site for viral replication and a significant reservoir for latent infection. Despite the success of antiretroviral therapy (ART) in suppressing plasma viremia, HIV persists indefinitely in latently infected cells, commonly found in the intestinal tract due to its unique immunological and structural environment. Targeting HIV-infected cells that persist in the intestinal tract is an important consideration for therapeutic strategies and is also important when considering an HIV cure. This review describes the therapeutic approaches aimed at addressing HIV persistence in the intestinal tract, or gut. We provide a brief overview of mechanisms underlying reservoir formation and maintenance, discuss the challenges posed by gut-specific factors, and examine emerging strategies, including latency reversal agents, immune modulation, gut-targeted ART, and novel delivery systems. This review will focus on contemporary advances in knowledge in this space, gaps in the literature and areas for future research focus.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2025.1650852